China Regulatory Probe Slows Nu Skin Growth After Record Year
This article was originally published in The Tan Sheet
Executive Summary
The firm’s recent explosive growth is expected to slow substantially in the first quarter – to between 20% and 24% – but Nu Skin is confident the steps it is taking in China “make our long-term success more likely.” Analysts have faith in the firm as it works with Chinese officials to resolve an investigation into its business practices.
You may also be interested in...
NUFA hearing
The Senate Committee on Health, Education, Labor & Pensions held a hearing on the National Uniformity for Food Act (S 3128) July 27. Witnesses included Peter Barton Hutt, Senior Counsel for Covington & Burling (Washington, D.C.), and former FDA Associate Commissioner for Policy William Hubbard. The HELP committee does not expect to vote on the legislation until after the August recess. NUFA was introduced in the House in October 2005. After the bill (H.R. 4167) passed the House in late February, it was referred to the Senate. The companion bill was introduced by Sen. Richard Burr (R-N.C.) May 25...
China Regulatory Probe Slows Nu Skin Growth After Record Year
The firm’s recent explosive growth is expected to slow substantially in the first quarter – to between 20% and 24% – but Nu Skin is confident the steps it is taking in China “make our long-term success more likely.” Analysts have faith in the firm as it works with Chinese officials to resolve an investigation into its business practices.
Nu Skin Projects 20%-24% Growth In Q1 Despite China Regulatory Probe
Analysts have faith in Nu Skin’s strategy, and future prospects, as it works with Chinese officials to resolve an investigation into its business practices in China. While the firm’s recent explosive growth is expected to fall off substantially in the first quarter of fiscal 2014 – to a more modest 20% to 24% – Nu Skin is confident that the steps it is taking in China “will make our long-term success more likely.”